CERTMEDIUM SIGNALFINANCIAL10-K

CERT achieved a dramatic turnaround from operating losses to profitability while significantly improving cash generation, despite higher interest costs.

The company's swing from a $1.7M operating loss to $21.0M operating income demonstrates improved operational efficiency and business momentum. However, the 28.9% increase in interest expense and continued net losses indicate ongoing financial pressures from debt servicing that are offsetting operational improvements.

Comparing 2026-02-26 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

CERT showed strong operational improvement with operating income swinging from negative $1.7M to positive $21.0M, while operating cash flow grew a robust 19.7% to $96.3M. However, rising interest expense (+28.9%) continued to weigh on bottom-line performance, keeping the company in net loss territory despite the significant reduction from -$12.1M to -$1.6M. The overall picture suggests a company successfully turning around its operations but still managing debt burden challenges.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+1314.1%
-$1.7M$21.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+86.8%
-$12.1M-$1.6M

Net income grew 86.8% — bottom-line growth signals improving overall business health.

Interest Expense
P&L
+28.9%
$17.8M$22.9M

Interest costs rose 28.9% — monitor debt levels and coverage ratio in rising rate environment.

Operating Cash Flow
Cash Flow
+19.7%
$80.5M$96.3M

Operating cash flow grew 19.7% — strong conversion of earnings to cash, healthy business fundamentals.

R&D Expense
P&L
+10.6%
$37.1M$41.0M

R&D investment increased 10.6% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-26
ADDED
As of February 17, 2026, the registrant had 159,139,562 shares of common stock, par value $0.01 per share, outstanding.
Our registered trademarks include Certara Phoenix, Simcyp, Pinnacle 21, CoAuthor, GlobalSubmit Certara D360, Chemaxon and Vyasa.
Operational disruptions, funding constraints and policy changes at the FDA and other government agencies could adversely affect regulatory activity and our business.
The loss of one or more of our major customers could materially and adversely affect our business, results of operations and/or financial condition.
Our Company We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development ( MIDD ) in the global biopharmaceutical and biotech industry.
+7 more — sign up free →
REMOVED
As of February 17, 2025, the registrant had 161,017,775 shares of common stock, par value $0.01 per share, outstanding.
Our registered trademarks include Certara , Phoenix , Simcyp , Pinnacle 21 , CoAuthor , GlobalSubmit , Certara D360 and Vyasa TM .
Our historic growth rates may not be sustainable or indicative of future growth.
We rely upon third-party providers of cloud-based infrastructure to host our software solutions.
Our Company We are a global leader in biosimulation technology and solutions for using Model-Informed Drug Development ( MIDD ) in the global biopharmaceutical industry.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →